Article Information
History
- February 20, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Yonggang Zhou1,2,3,#,
- Binqing Fu1,2,#,
- Xiaohu Zheng1,2,#,
- Dongsheng Wang3,
- Changcheng Zhao3,
- Yingjie qi3,
- Rui Sun1,2,
- Zhigang Tian1,2,
- Xiaoling Xu3,* and
- Haiming Wei1,2,4,*
- 1Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui 230001, China
- 2Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui 230001, China
- 3The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China
- ↵*Correspondence: ustcwhm{at}ustc.edu.cn (H.W.); xxlahh8{at}ustc.edu.cn (X.X.)
↵# These authors contributed equally
Posted February 20, 2020.
Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus
